Antibiotic usage and resistance: Gaining or losing ground on infections in critically ill patients?

JAMA

Volumn 302, Issue 21, 2009, Pages 2367-2368

  Opal, Steven M ^a   Calandra, Thierry ^b,c  

^a BROWN UNIVERSITY   (United States)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; EDITORIAL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEALTH CARE QUALITY; HOSPITAL INFECTION; HOST PATHOGEN INTERACTION; HUMAN; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; PREVALENCE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; COST OF ILLNESS; CRITICAL ILLNESS; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; HUMANS; INFECTION; INTENSIVE CARE UNITS; WORLD HEALTH;

EID: 72249119414     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1774     Document Type: Editorial

References (12)

1. Vincent J-L, Rello J, Marshall J, et al; for the EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323-2329.
2. Vincent J-L, Bihari D, Suter PM, et al; EPIC International Advisory Committee. The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC Study). JAMA. 1995; 274(8):639-644.
3. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348(16):1546-1554.
4. Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis. 2007;45(9):1179-1181. (Pubitemid 47580316)
5. Barchitta M, Cipresso R, Giaquinta L, et al. Acquisition and spread of Acinetobacter baumannii and Stenotrophomonas maltophilia in intensive care patients. Int J Hyg Environ Health. 2009;212(3):330-337.
6. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG; Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis. 2006;42(5):657-668.
7. Spencer RC. Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study. Eur J Clin Microbiol Infect Dis. 1996;15(4): 281-285.
8. Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada [published online ahead of print October 12, 2009]. JAMA. 2009;302(17):1872-1879.
9. Opal SM, Pop-Vicas A. Molecular mechanisms of antibiotic resistance in bacteria. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Elsevier; 2009: 279-296.
10. Calandra T, Cohen J; International Sepsis Forum Definition of Infection in the ICU Consensus Conference. The International Sepsis Forum Concensus Conference on Definitions of Infection in the Intensive Care Unit. Crit Care Med. 2005; 33(7):1538-1548.
11. Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2): S27-S72.
12. Schuetz P, Christ-Crain M, Thomann R, et al; ProHOSP Study Group. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use for lower respiratory tract infections. JAMA. 2009;302(10):1059-1066.